Hemorrheologic abnormalities in defined primary dyslipoproteinemias with both high and low atherosclerotic risks

Dyslipoproteinemias are associated with hemorrheologic abnormalities (elevated fibrinogen concentration, higher viscosity of plasma and blood). Epidemiologic data suggest that not only elevated lipoprotein concentrations (eg, low-density lipoprotein [LDL] cholesterol), but also hemorrheologic abnorm...

Full description

Saved in:
Bibliographic Details
Published in:Metabolism, clinical and experimental clinical and experimental, 2001-02, Vol.50 (2), p.166-170
Main Authors: Otto, Carsten, Ritter, Michael M., Richter, Werner O., Minkenberg, Ralf, Schwandt, Peter
Format: Article
Language:English
Subjects:
Arteriosclerosis - blood
Arteriosclerosis - complications
Arteriosclerosis - etiology
Biological and medical sciences
Blood Viscosity
Cross-Sectional Studies
Disorders of blood lipids. Hyperlipoproteinemia
Female
Fibrinogen - analysis
Hematocrit
Hemorheology
Humans
Hyperlipoproteinemia Type II - blood
Hyperlipoproteinemia Type II - complications
Hyperlipoproteinemia Type IV - blood
Hyperlipoproteinemia Type IV - complications
Hyperlipoproteinemias - blood
Hyperlipoproteinemias - complications
Lipoproteins - blood
Male
Medical sciences
Metabolic diseases
Middle Aged
Risk Factors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dyslipoproteinemias are associated with hemorrheologic abnormalities (elevated fibrinogen concentration, higher viscosity of plasma and blood). Epidemiologic data suggest that not only elevated lipoprotein concentrations (eg, low-density lipoprotein [LDL] cholesterol), but also hemorrheologic abnormalities could causally be involved in the atherosclerotic process. To elucidate potential effects of hemorrheological disturbances, we investigated patients suffering from primary hyperlipoproteinemias with both low (familial hypertriglyceridemia, n = 25) and high (type III hyperlipoproteinemia, n = 21; familial hypercholesterolemia, n = 19; mixed hyperlipoproteinemia, n = 19) atherosclerotic risk, as well as healthy controls (n = 49) in a cross-sectional design. Dyslipoproteinemias were classified by lipoprotein measurements (using ultracentrifugation), family history, and apolipoprotein E phenotype. Hemorrheology was characterized by the measurement of fibrinogen concentration, viscosity of plasma and blood at different shear rates, and red cell aggregation (RCA) at stasis and low shear. Fibrinogen concentration was lower in controls (2.38 ± 0.09 g/L) compared with familial hypercholesterolemia (3.19 ± 0.19 g/L), to type III hyperlipoproteinemia (3.02 ± 0.12 g/L), to familial hypertriglyceridemia (2.95 ± 0.21 g/L) and to mixed hyperlipoproteinemia (3.01 ± 0.12 g/L) ( P < .05, respectively) without differences between dyslipoproteinemia groups. Plasma viscosity was higher in patients with type III hyperlipoproteinemia (1.42 ± 0.03 mPas), with familial hypertriglyceridemia (1.47 ± 0.04 mPas), and with mixed hyperlipoproteinemia (1.43 ± 0.02 mPas) compared with controls (1.29 ± 0.01 mPas) ( P < .05, respectively). After including 6 lipoprotein parameters in a general linear model, plasma viscosity, blood viscosity, and RCA were higher in familial hypertriglyceridemia compared with healthy controls and familial hypercholesterolemia ( P < .05, respectively). As most of the hemorrheologic abnormalities were still significant after adjusting for lipoprotein concentrations, they seem to be at least partly independent from direct lipoprotein effects. Hemorrheologic abnormalities in familial hypertriglyceridemia (low atherosclerotic risk) were at least as marked as in dyslipoproteinemias with high atherosclerotic risk, suggesting that it might be most important to determine lipoprotein concentrations and to define exactly the type of dyslipoproteinemia for estimating th
ISSN:0026-0495
1532-8600
DOI:10.1053/meta.2001.20192